AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 780001 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29788815 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium loading dose (7.5 g of magnesium sulfate in 500 mL normal saline as intravenous infusion over an 8-hour period)
Number of subjects: 70
Study 29788815 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium loading dose
Number of subjects: 70
Study 30648561 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal transplantation
Number of subjects: 27
Study 30648561 — intervention group
Group type: COMPARATOR
Intervention: Pre-nephrectomy transplant evaluation
Number of subjects: 27
Study 30648561 — intervention group
Group type: COMPARATOR
Intervention: cT1a renal parenchymal mass
Number of subjects: 27
Study 28222818 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pricing and communications intervention
Number of subjects: 24
Study 28222818 — intervention group
Group type: COMPARATOR
Intervention: Pricing intervention
Number of subjects: 24
Study 28222818 — intervention group
Group type: COMPARATOR
Intervention: Communications intervention
Number of subjects: 24
Study 28222818 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 25384603 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) group, 150 mg/kg IV bolus at anaesthetic induction followed by continuous infusion at 150 mg/kg per day for 24 hours.
Number of subjects: 117
Study 25384603 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NAC treatment)
Number of subjects: 117
Study 25384603 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC group
Number of subjects: 117
Study 25384603 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study 22530610 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and isoflavones (Ex-Iso; n = 26)
Number of subjects: 54
Study 22530610 — intervention group
Group type: COMPARATOR
Intervention: Exercise and placebo (Ex-Pla; n = 28)
Number of subjects: 54
Study 21514083 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1800
Study 21514083 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 1800
Study 19966634 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (stimulator ON)
Number of subjects: 19
Study 19966634 — intervention group
Group type: COMPARATOR
Intervention: Sacral nerve stimulation (stimulator OFF)
Number of subjects: 19
Study 17428318 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone coaching intervention (8 sessions over 18 months plus usual care)
Number of subjects: 546
Study 17428318 — intervention group
Group type: COMPARATOR
Intervention: Usual care from GPs
Number of subjects: 546
Study 15311010 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral stent
Number of subjects: 32
Study 15311010 — intervention group
Group type: COMPARATOR
Intervention: Standard stent
Number of subjects: 32
Study 11212970 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens alone
Number of subjects: 69
Study 11212970 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogens plus medroxyprogesterone
Number of subjects: 69
Study 11212970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 11212970 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement (both active groups)
Number of subjects: 69
Study 9609581 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline 5 mg every 6 hours for 24 hours
Number of subjects: 6
Study 8002057 — intervention group
Group type: EXPERIMENTAL
Intervention: KREATECH IgA ELISA test
Number of subjects: 71
Study 2074253 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime 1.0 g
Number of subjects: 0
Study 2074253 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime 2.0 g
Number of subjects: 0
Study 415356 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepacrine hydrochloride
Number of subjects: 25
Study 415356 — intervention group
Group type: COMPARATOR
Intervention: Triethylenethiophosphoramide (Thiotepa)
Number of subjects: 25
Study 415356 — intervention group
Group type: COMPARATOR
Intervention: Pleurocentesis alone
Number of subjects: 25
Study 31186173 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation (prehab group)
Number of subjects: 70
Study 31186173 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 70
Study 31421469 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy
Number of subjects: 189
Study 31421469 — intervention group
Group type: EXPERIMENTAL
Intervention: GP induction chemotherapy
Number of subjects: 189
Study 31421469 — intervention group
Group type: COMPARATOR
Intervention: CCRT alone
Number of subjects: 189
Study 28645713 — intervention group
Group type: EXPERIMENTAL
Intervention: Q6 dosing strategy (n=4)
Number of subjects: 26
Study 28645713 — intervention group
Group type: EXPERIMENTAL
Intervention: Q8 dosing strategy (n=6)
Number of subjects: 26
Study 28645713 — intervention group
Group type: EXPERIMENTAL
Intervention: Q24 dosing strategy (n=6)
Number of subjects: 26
Study 28645713 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n=10)
Number of subjects: 26
Study 28645713 — intervention group
Group type: EXPERIMENTAL
Intervention: Q6 vs Q8
Number of subjects: 26
Study 25290526 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief smoking cessation intervention
Number of subjects: 354
Study 23769665 — intervention group
Group type: EXPERIMENTAL
Intervention: Blastocyst cryopreservation
Number of subjects: 1190
Study 23769665 — intervention group
Group type: COMPARATOR
Intervention: Cleavage-stage embryo cryopreservation (control group)
Number of subjects: 1190
Study 21612749 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone GPO® (Test)
Number of subjects: 23
Study 21612749 — intervention group
Group type: COMPARATOR
Intervention: Risperdal® (Reference)
Number of subjects: 23
Study 18637935 — intervention group
Group type: EXPERIMENTAL
Intervention: PTQ (injectable silicone biomaterial)
Number of subjects: 40
Study 18637935 — intervention group
Group type: COMPARATOR
Intervention: Durasphere (carbon-coated beads)
Number of subjects: 40
Study 17925114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclofem
Number of subjects: 68
Study 17925114 — intervention group
Group type: COMPARATOR
Intervention: DMPA
Number of subjects: 68
Study 15089817 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine controlled-release (CR) 20-40 mg daily
Number of subjects: 25
Study 15089817 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine retard 20-40 mg daily
Number of subjects: 25
Study 11386476 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin)
Number of subjects: 32
Study 11386476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 8703451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 41
Study 8703451 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 41
Study 1286640 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotiana tabacum (snuff) with Natron 0.5g/100g
Number of subjects: 33
Study 1286640 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotiana tabacum (snuff) with Natron 10g/100g
Number of subjects: 33
Study 1286640 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotiana tabacum (snuff) without Natron
Number of subjects: 33
Study 3931910 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 0
Study 3931910 — intervention group
Group type: COMPARATOR
Intervention: No selenium supplementation
Number of subjects: 0
Study 3931910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac enzyme activity measurement
Number of subjects: 0
Study 31680225 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga practice for 1 hour, 2 times a week for 12 weeks
Number of subjects: 30
Study 31680225 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated with yoga, given lung rehabilitation brochure)
Number of subjects: 30
Study 30537959 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexical approach to identifying inconsistencies in SNOMED CT modeling
Number of subjects: 50
Study 27471813 — intervention group
Group type: EXPERIMENTAL
Intervention: D (Dentistar)
Number of subjects: 121
Study 27471813 — intervention group
Group type: EXPERIMENTAL
Intervention: N (NUK)
Number of subjects: 121
Study 27471813 — intervention group
Group type: COMPARATOR
Intervention: C (no pacifier)
Number of subjects: 121
Study 24697870 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor IX (Bax326)
Number of subjects: 14
Study 23705344 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal Music Therapy (MMT)
Number of subjects: 36
Study 23705344 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 36
Study 18469160 — intervention group
Group type: EXPERIMENTAL
Intervention: MBSR-ld
Number of subjects: 42
Study 18469160 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 17845588 — intervention group
Group type: EXPERIMENTAL
Intervention: Xolair (omalizumab) treatment for 6 years followed by withdrawal
Number of subjects: 18
Study 17845588 — intervention group
Group type: EXPERIMENTAL
Intervention: Xolair withdrawal
Number of subjects: 18
Study 16329362 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sequential LASIK
Number of subjects: 335
Study 16329362 — intervention group
Group type: COMPARATOR
Intervention: Bilateral simultaneous LASIK
Number of subjects: 335
Study 12488405 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin plus Tamoxifen (3 years of goserelin plus 5 years of tamoxifen)
Number of subjects: 1034
Study 12488405 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) (six cycles)
Number of subjects: 1034
Study 9798529 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP (7.5 ng/kg/min) infusion during high salt diet
Number of subjects: 20
Study 9798529 — intervention group
Group type: COMPARATOR
Intervention: Placebo during high salt diet
Number of subjects: 20
Study 9798529 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP infusion during low salt diet
Number of subjects: 20
Study 9798529 — intervention group
Group type: COMPARATOR
Intervention: Placebo during low salt diet
Number of subjects: 20
Study 8566922 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphite furnace atomic absorption spectrophotometry (GFAAS) method for manganese determination
Number of subjects: 1
Study 2611070 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 40
Study 2611070 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 40
Study 2611070 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 57815 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 14
Study 31775780 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-based biofeedback device
Number of subjects: 14
Study 31775780 — intervention group
Group type: COMPARATOR
Intervention: No biofeedback device (control)
Number of subjects: 14
Study 27524737 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous interferential electrical stimulation plus behavioral therapy
Number of subjects: 30
Study 27524737 — intervention group
Group type: COMPARATOR
Intervention: Behavioral therapy alone
Number of subjects: 30
Study 25794202 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of lidocaine 2%
Number of subjects: 57
Study 25794202 — intervention group
Group type: COMPARATOR
Intervention: 4 mL of lidocaine 2% + 1 mL of betametazone
Number of subjects: 57
Study 22776698 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramped methodology
Number of subjects: 10
Study 22776698 — intervention group
Group type: COMPARATOR
Intervention: Random methodology
Number of subjects: 10
Study 20537740 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized iloprost (n = 50)
Number of subjects: 75
Study 20537740 — intervention group
Group type: COMPARATOR
Intervention: Intravenous adenosine (n = 25)
Number of subjects: 75
Study 19643961 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom‐designed soft contact lenses with altered ocular SA to ‐0.10 microm
Number of subjects: 93
Study 19643961 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision training regimen for 18 minutes per day for up to 6 weeks
Number of subjects: 93
Study 19643961 — intervention group
Group type: COMPARATOR
Intervention: Control groups had contact lenses with no added SA and/or no exercises
Number of subjects: 93
Study 17236861 — intervention group
Group type: EXPERIMENTAL
Intervention: Suturing in full complexity under 2-dimensional conditions
Number of subjects: 24
Study 17236861 — intervention group
Group type: COMPARATOR
Intervention: Simple cone transfer drills under 3-dimensional and then 2-dimensional conditions, followed by suturing under 3-dimensional and then 2-dimensional conditions
Number of subjects: 24
Study 15533855 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 75 mg
Number of subjects: 633
Study 15533855 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 125 mg
Number of subjects: 633
Study 15533855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study 10642679 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (divided doses for 14 days)
Number of subjects: 90
Study 10642679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 9050958 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal lobe oriented computed tomography (CT)
Number of subjects: 333
Study 8156249 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy regimen 1
Number of subjects: 127
Study 8156249 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy regimen 2
Number of subjects: 127
Study 8156249 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall quality of life assessment
Number of subjects: 127
Study 8156249 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 127
Study 2423794 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (75 mg/day for 2 weeks)
Number of subjects: 16
Study 2423794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31836594 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure using Semen Vaccariae (Group A)
Number of subjects: 100
Study 31836594 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure using magnetic beads (Group B)
Number of subjects: 100
Study 31836594 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Group C)
Number of subjects: 100
Study 31691305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 152
Study 31691305 — intervention group
Group type: EXPERIMENTAL
Intervention: Return-to-Work Intervention (RTW-I)
Number of subjects: 152
Study 31691305 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBT and RTW-I (COMBO)
Number of subjects: 152
Study 28422520 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT-135 J
Number of subjects: 20
Study 28422520 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT-270 J
Number of subjects: 20
Study 28422520 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT-405 J
Number of subjects: 20
Study 28422520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28395886 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 3385
Study 25777187 — intervention group
Group type: EXPERIMENTAL
Intervention: rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF)
Number of subjects: 786
Study 25777187 — intervention group
Group type: COMPARATOR
Intervention: efavirenz/emtricitabine/tenofovir DF (EFV/FTC/TDF)
Number of subjects: 786
Study 24241787 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 5 mg/day
Number of subjects: 0
Study 24241787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide
Number of subjects: 0
Study 24241787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24241787 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents (Tamoxifen and Fenretinide)
Number of subjects: 0
Study 24241787 — intervention group
Group type: EXPERIMENTAL
Intervention: SHBG levels
Number of subjects: 0
Study 21178084 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/d of algal DHA
Number of subjects: 36
Study 18509560 — intervention group
Group type: EXPERIMENTAL
Intervention: SEAS exercises
Number of subjects: 74
Study 18509560 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy
Number of subjects: 74
Study 16921042 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance paclitaxel
Number of subjects: 255
Study 16921042 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional chemotherapy)
Number of subjects: 255
Study 12656936 — intervention group
Group type: EXPERIMENTAL
Intervention: Right prefrontal TMS
Number of subjects: 25
Study 12656936 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 25
Study 10634672 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist Device (LVAD)
Number of subjects: 8
Study 10634672 — intervention group
Group type: COMPARATOR
Intervention: Heart transplantation without LVAD (Control)
Number of subjects: 8
Study 10634672 — intervention group
Group type: COMPARATOR
Intervention: Non-heart failure controls (Autopsy hearts)
Number of subjects: 8
Study 8944192 — intervention group
Group type: EXPERIMENTAL
Intervention: BrAC 0.1%
Number of subjects: 22
Study 8944192 — intervention group
Group type: EXPERIMENTAL
Intervention: BrAC 0.05%
Number of subjects: 22
Study 8944192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 1758414 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration therapy using a resorbable membrane
Number of subjects: 0
Study 1758414 — intervention group
Group type: COMPARATOR
Intervention: Guided tissue regeneration therapy using a nonresorbable membrane
Number of subjects: 0
Study 7045255 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% acyclovir (ACV) in polyethylene glycol (PEG)
Number of subjects: 208
Study 7045255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 30012431 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (10 mg twice daily, n = 905)
Number of subjects: 1139
Study 30012431 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 234)
Number of subjects: 1139
Study 27154976 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost infusion plus standardized protocol of peroneal nerve electrostimulation (1 Hz frequency, 27 mA current, 200 ms pulse width)
Number of subjects: 22
Study 27154976 — intervention group
Group type: COMPARATOR
Intervention: Iloprost infusion protocol alone
Number of subjects: 22
Study 27154976 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Iloprost infusion alone and Iloprost infusion plus electrostimulation)
Number of subjects: 22
Study 27154976 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 26370136 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium (400 μg, bd)
Number of subjects: 263
Study 26370136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 23581798 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinpoint irradiation technique by CO2 laser without needling
Number of subjects: 60
Study 23581798 — intervention group
Group type: COMPARATOR
Intervention: Pinpoint irradiation technique by CO2 laser with needling
Number of subjects: 60
Study 21707679 — intervention group
Group type: EXPERIMENTAL
Intervention: ANA773 2000mg
Number of subjects: 34
Study 21707679 — intervention group
Group type: EXPERIMENTAL
Intervention: ANA773 1600mg
Number of subjects: 34
Study 21707679 — intervention group
Group type: EXPERIMENTAL
Intervention: ANA773 1200mg
Number of subjects: 34
Study 21707679 — intervention group
Group type: EXPERIMENTAL
Intervention: ANA773 800mg
Number of subjects: 34
Study 21707679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 19628104 — intervention group
Group type: EXPERIMENTAL
Intervention: Waxy maize starch (WM)
Number of subjects: 12
Study 19628104 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin-sucrose mixture (MS)
Number of subjects: 12
Study 19628104 — intervention group
Group type: COMPARATOR
Intervention: White bread (control)
Number of subjects: 12
Study 19628104 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial energy expenditure and appetite
Number of subjects: 12
Study 16924341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone applied to ultrasonic cleaning system with sterile distilled water
Number of subjects: 1
Study 16924341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone applied to ultrasonic cleaning system with vinegar
Number of subjects: 1
Study 16924341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone applied to ultrasonic cleaning system with sterile distilled water + Endozime AWpluz
Number of subjects: 1
Study 14685870 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (0.3 g/kg per day)
Number of subjects: 17
Study 14685870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 11986017 — intervention group
Group type: EXPERIMENTAL
Intervention: Active mechanical massage by intermittent negative pressure on the abdominal wall (Cellu M50 device, LPG, Valence, France); performed daily until the seventh postoperative day.
Number of subjects: 50
Study 11986017 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (no active mechanical massage); ineffective parameters used.
Number of subjects: 50
Study 11986017 — intervention group
Group type: EXPERIMENTAL
Intervention: Active mechanical massage group; performed daily until the seventh postoperative day.
Number of subjects: 50
Study 9876753 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 85
Study 9876753 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide
Number of subjects: 85
Study 9876753 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic treatment (ondansetron or metoclopramide) in males
Number of subjects: 85
Study 9876753 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ondansetron in females
Number of subjects: 85